Clinical Trials Directory

Trials / Completed

CompletedNCT00754000

The AIM Study: Assessing the Impact of Margin Reduction

Status
Completed
Phase
Study type
Observational
Enrollment
82 (actual)
Sponsor
Varian, a Siemens Healthineers Company · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will observe patients who receive external beam radiation for prostate cancer. These patients will be localized and tracked (targeted) with the Calypso 4D Localization System. These patients will have a uniform treatment plan with reduced PTVs (prostate treatment volume) and will be assessed at multiple time points for quality of life and side effects related to radiation therapy.

Detailed description

EPIC surveys and adverse events recorded and categorized using the CTCAE v3.0 will be collected and summary statistics performed. The patient's individual tracking graphs will be evaluated for motion type and frequency.

Conditions

Interventions

TypeNameDescription
OTHERObservationAE monitoring and EPIC QOL survey

Timeline

Start date
2008-07-01
Completion
2009-09-01
First posted
2008-09-17
Last updated
2012-04-30

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00754000. Inclusion in this directory is not an endorsement.

The AIM Study: Assessing the Impact of Margin Reduction (NCT00754000) · Clinical Trials Directory